Caplin Point listed on Forbes Asia’s “200 Best Under a Billion” for 2023

Caplin Point Laboratories Ltd has been recognized in Forbes Asia’s 200 Best Under a Billion list for the year 2023, a compilation that underscores companies’ sustained and robust performance across critical benchmarks. Carefully selected from a substantial pool of more than 20,000 publicly traded companies across the Asia-Pacific region, the chosen 200 enterprises showcase annual sales under $1 billion. The comprehensive criteria encompasses evaluation of debt management, sales growth, earnings-per-share performance, as well as returns on equity

Commenting on the achievement, Mr. C.C. Paarthipan, Chairman said: “The inclusion of Caplin Point Laboratories Ltd in Forbes Asia’s ‘200 Best Under a Billion’ list for 2023 is a testament to our dedication to excellence. This marks our 6th appearance on this list in the last decadeā€”a prestigious achievement for an Indian pharmaceutical company. We remain focused on strengthening cash flows and ensuring consistent profitability and this recognition reaffirms our commitment to these financial goals.”